CellSource Co., Ltd. (4880.T)
JPY 644.0
(-1.38%)
JPY 644.0
(-1.38%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.51 Billion JPY | 5.54% |
| 2022 | 4.27 Billion JPY | 46.25% |
| 2021 | 2.92 Billion JPY | 57.49% |
| 2020 | 1.85 Billion JPY | 15.13% |
| 2019 | 1.61 Billion JPY | 32.89% |
| 2018 | 1.21 Billion JPY | 133.64% |
| 2017 | 519.06 Million JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.05 Billion JPY | -10.17% |
| 2024 Q1 | 1.17 Billion JPY | 6.26% |
| 2024 Q3 | 1.11 Billion JPY | 5.65% |
| 2023 Q3 | 1.23 Billion JPY | 11.2% |
| 2023 FY | 4.51 Billion JPY | 5.54% |
| 2023 Q4 | 1.1 Billion JPY | -10.61% |
| 2023 Q2 | 1.11 Billion JPY | 4.87% |
| 2023 Q1 | 1.05 Billion JPY | -24.36% |
| 2022 Q4 | 1.4 Billion JPY | 19.12% |
| 2022 FY | 4.27 Billion JPY | 46.25% |
| 2022 Q2 | 876.1 Million JPY | 6.72% |
| 2022 Q1 | 820.91 Million JPY | 0.36% |
| 2022 Q3 | 1.17 Billion JPY | 34.23% |
| 2021 Q2 | 720.44 Million JPY | 15.7% |
| 2021 Q1 | 622.68 Million JPY | 14.57% |
| 2021 Q3 | 761.14 Million JPY | 5.65% |
| 2021 Q4 | 817.96 Million JPY | 7.47% |
| 2021 FY | 2.92 Billion JPY | 57.49% |
| 2020 Q4 | 543.51 Million JPY | 27.68% |
| 2020 Q2 | 441.86 Million JPY | -0.58% |
| 2020 Q1 | 444.42 Million JPY | 1.15% |
| 2020 FY | 1.85 Billion JPY | 15.13% |
| 2020 Q3 | 425.67 Million JPY | -3.66% |
| 2019 FY | 1.61 Billion JPY | 32.89% |
| 2019 Q4 | 439.38 Million JPY | 0.0% |
| 2018 FY | 1.21 Billion JPY | 133.64% |
| 2017 FY | 519.06 Million JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 4.77 Billion JPY | 5.441% |
| PRISM BioLab Co.,LTD | 112.92 Million JPY | -3894.248% |
| GNI Group Ltd. | 26.01 Billion JPY | 82.659% |
| Linical Co., Ltd. | 12.3 Billion JPY | 63.352% |
| Trans Genic Inc. | 13.08 Billion JPY | 65.525% |
| MEDINET Co., Ltd. | 661.54 Million JPY | -581.822% |
| Soiken Holdings Inc. | 5.15 Billion JPY | 12.56% |
| Cytori Cell Research Institute, Inc. | 1.56 Billion JPY | -189.066% |
| AnGes, Inc. | 152.98 Million JPY | -2848.357% |
| OncoTherapy Science, Inc. | 610.11 Million JPY | -639.29% |
| Nxera Pharma Co., Ltd. | 12.76 Billion JPY | 64.668% |
| Immuno-Biological Laboratories Co., Ltd. | 816.7 Million JPY | -452.288% |
| NanoCarrier Co., Ltd. | 135.5 Million JPY | -3228.618% |
| Carna Biosciences, Inc. | 1.62 Billion JPY | -177.42% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 428.36 Million JPY | -952.97% |
| RaQualia Pharma Inc. | 1.9 Billion JPY | -137.247% |
| Chiome Bioscience Inc. | 682.46 Million JPY | -560.92% |
| Kidswell Bio Corporation | 2.43 Billion JPY | -85.525% |
| PeptiDream Inc. | 28.71 Billion JPY | 84.29% |
| Oncolys BioPharma Inc. | 63.03 Million JPY | -7055.278% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | 121 Million JPY | -3627.722% |
| BrightPath Biotherapeutics Co., Ltd. | 72 Thousand JPY | -6264544.444% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 39.88 Million JPY | -11208.306% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| FunPep Company Limited | 530 Thousand JPY | -850946.038% |
| Kringle Pharma, Inc. | 69.25 Million JPY | -6413.421% |
| Stella Pharma Corporation | 269.49 Million JPY | -1573.727% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | 316.81 Million JPY | -1323.702% |
| Cuorips Inc. | 23.1 Million JPY | -19424.474% |
| K Pharma,Inc. | 1 Billion JPY | -351.054% |
| Takara Bio Inc. | 43.5 Billion JPY | 89.632% |
| ReproCELL Incorporated | 2.42 Billion JPY | -85.863% |
| PhoenixBio Co., Ltd. | 1.71 Billion JPY | -162.956% |
| StemCell Institute Inc. | 2.48 Billion JPY | -81.789% |
| Japan Tissue Engineering Co., Ltd. | 2.51 Billion JPY | -79.403% |
| CellSeed Inc. | 190.13 Million JPY | -2272.297% |